| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ358 in Patients with Congenital Hyperinsulinism |
Ongoing |
RZ358 |
3 |
RZ358-301 |
King Abdulaziz Medical City NG (Riyadh) |
| Modified Quadruple Therapy Regimen for Helicobacter pylori Eradication – A Prospective Randomized Controlled Trial |
Ongoing |
Bismuth Subcitrate Potassium , Tetracycline , Metronidazol |
2 |
2231295 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER |
Ongoing |
Giredestrant , Phesgo |
3 |
WO43571 |
King Abdulaziz Medical City NG (Riyadh) , King Fahad Medical City (Riyadh) |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension |
Ongoing |
Baxdrostat |
3 |
D6970C00009 |
King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh) |
| The effect of novel D3 use as a mouthwash in COVID-19 patients |
Ongoing |
Cholecalciferol (vitamin D) |
3 |
2022-32 |
King Faisal Specialist Hospital and Research Center (Jeddah) |
| Multinational Survey-Based Chart Review Study in International Markets to Evaluate the Effectiveness, Safety, and Treatment Patterns of DUPIXENT® (Dupilumab) in Patients with Moderate-to-Severe Atopic Dermatitis |
Completed |
DUPIXENT® (Dupilumab) |
4 |
DUT0012 |
Specialized Medical Center (Riyadh),Dr. Erfan & Bagedo General Hospital (Jeddah) |
| Nucala Effectiveness Study (NEST) in Emerging Markets |
Completed |
Mepolizumab |
3 |
213475 |
King Fahad University Hospital (Al-Khobar) |
| A multi-national, multi-centre, prospective, single-arm, observational, non-interventional post-authorisation safety study to investigate long-term safety of Sogroya®(somapacitan) in adults with growth hormone deficiency (AGHD) under routine clinical practice |
Ongoing |
Sogroya® |
4 |
NN8640-451 |
My Clinic (Jeddah),King Fahad Medical City (Riyadh),Dr. Sulaiman Al-Habib Medical Group Olaya (Riyadh) |
| A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects with Propionic or Methylmalonic Acidemia Followed by a 6-Month, Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study and an Open-label, Long-term Extension Study |
Terminated |
ST5040 (2,2-dimethylbutanoic acid) |
4 |
HST20-CL01 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Early Sedation with Dexmedetomidine vs. Placebo in Older Ventilated Critically Ill Patients A Prospective, Multi-Centre, Double-Blind, Randomized, Controlled Trial. SPICE IV |
Ongoing |
DEXMEDETOMIDINE |
4 |
SCT21R/006/04 |
King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
